Baillie Gifford & Co Portfolio holdings
Baillie Gifford & Co., founded in 1908 by Lt Col Augustus Baillie and Carlyle Gifford and headquartered in Edinburgh, Scotland, is an independent, partnership-owned investment management firm renowned for its long-term, growth-oriented approach, managing over £230 billion ($290 billion USD) in assets as of late 2024. Focusing primarily on global equities, the firm serves institutional clients like pension funds and retail investors through mutual funds and investment trusts, such as the Scottish Mortgage Investment Trust, emphasizing fundamental research into innovative, high-growth companies—often holding stakes in firms like Tesla and Amazon for decades. With around 2,000 employees across offices in London, New York, Hong Kong, and beyond, Baillie Gifford operates without external ownership pressures, allowing its 58 partners to prioritize patience and conviction over short-term market trends. Known for its low-profile culture and ESG integration, the firm has earned a reputation as a thoughtful, contrarian investor in a world of rapid-fire trading.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Moderna
MRNA
|
+$1.04B |
| 2 |
Affirm
AFRM
|
+$731M |
| 3 |
SCHW
Charles Schwab
SCHW
|
+$607M |
| 4 |
FTCH
Farfetch Limited Class A Ordinary Shares
FTCH
|
+$565M |
| 5 |
Carvana
CVNA
|
+$533M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Tesla
TSLA
|
+$3.07B |
| 2 |
Full Truck Alliance
YMM
|
+$1.57B |
| 3 |
ResMed
RMD
|
+$715M |
| 4 |
NVIDIA
NVDA
|
+$647M |
| 5 |
Alibaba
BABA
|
+$597M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Consumer Discretionary | 26.6% |
| 2 | Healthcare | 23.23% |
| 3 | Technology | 20.07% |
| 4 | Communication Services | 12.81% |
| 5 | Financials | 6.12% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
NCNA
251
NuCana
NCNA
$6.12M
| $8.71M | ﹤0.01% |
732
| – | – |
|
252
BridgeBio Pharma
BBIO
$16.5B
| $8.17M | ﹤0.01% |
489,721
+23,845
| +5% | +$1.01M |
|
253
Smartbird Inc
BIRD
$22.3M
| $8.03M | ﹤0.01% |
+26,625
| New | +$9.97M |
|
|
OCFT
254
DELISTED
OneConnect Financial Technology
OCFT
| $7.47M | ﹤0.01% |
302,444
+5,129
| +2% | +$152K |
|
255
Fortive
FTV
$18.6B
| $7.46M | ﹤0.01% |
129,799
| – | – |
|
256
Alector
ALEC
$199M
| $7.43M | ﹤0.01% |
359,724
+19,372
| +6% | +$437K |
|
257
Relay Therapeutics
RLAY
$4.33B
| $6.91M | ﹤0.01% |
225,041
+11,952
| +6% | +$378K |
|
258
TJX Companies
TJX
$178B
| $6.6M | ﹤0.01% |
86,893
| – | – |
|
|
MTLS
259
Materialise
MTLS
$396M
| $6.4M | ﹤0.01% |
+268,000
| New | +$6.23M |
|
260
Lyell Immunopharma
LYEL
$360M
| $5.6M | ﹤0.01% |
36,169
+14,795
| +69% | +$3.3M |
|
|
SAGE
261
DELISTED
Sage Therapeutics
SAGE
| $3.85M | ﹤0.01% |
90,372
+4,074
| +5% | +$171K |
|
262
American Well
AMWL
$230M
| $3.74M | ﹤0.01% |
30,964
+5,836
| +23% | +$890K |
|
|
SOHU
263
Sohu.com
SOHU
$357M
| $3.26M | ﹤0.01% |
200,140
| – | – |
|
264
Adicet Bio
ACET
$74.7M
| $3.18M | ﹤0.01% |
11,352
| – | – |
|
265
Spire Global
SPIR
$555M
| $2.93M | ﹤0.01% |
108,256
| – | – |
|
|
UXIN
266
Uxin Ltd
UXIN
$282M
| $2.81M | ﹤0.01% |
17,761
| – | – |
|
267
Axogen
AXGN
$2.5B
| $2.36M | ﹤0.01% |
251,435
-910,224
| -78% | -$10.9M |
|
|
KLDO
268
DELISTED
Kaleido Biosciences, Inc. Common Stock
KLDO
| $1.72M | ﹤0.01% |
721,512
+62,285
| +9% | +$254K |
|
269
WEC Energy
WEC
$35.1B
| $1.71M | ﹤0.01% |
17,566
+2,333
| +15% | +$213K |
|
270
Exelon
EXC
$47B
| $1.52M | ﹤0.01% |
36,866
+5,646
| +18% | +$213K |
|
271
Fortis
FTS
$28.7B
| $1.51M | ﹤0.01% |
31,332
+875
| +3% | +$39.6K |
|
272
Novanta
NOVT
$6.29B
| $1.26M | ﹤0.01% |
7,176
+6,970
| +3,383% | +$1.16M |
|
273
Newmont
NEM
$119B
| $1.25M | ﹤0.01% |
20,172
| – | – |
|
274
Xencor
XNCR
$1.55B
| $1.18M | ﹤0.01% |
29,307
+28,048
| +2,228% | +$1.06M |
|
275
Summit Therapeutics
SMMT
$11.1B
| $1.17M | ﹤0.01% |
436,512
| – | – |
|
Similar funds
Baillie Gifford & Co's Q4 2021 Portfolio in Review
As of Q4 2021, Baillie Gifford & Co held 518 positions worth $182B, down 4.7% from $191B the previous quarter. Its ten largest holdings account for 40% of the portfolio.
Baillie Gifford & Co's Q4 2021 filing shows 26 new, 181 increased, 122 reduced and 19 closed positions. Its largest new stake was Charles Schwab: 7,506,268 shares worth $631M. The largest sale was Tesla, an estimated $3.07B.
By sector, the portfolio is most concentrated in Consumer Discretionary at 27% of assets, down from 28% a quarter earlier, followed by Healthcare and Technology.
- Baillie Gifford & Co's largest Q4 2021 buy was Charles Schwab: 7,506,268 shares worth $631M.
- Baillie Gifford & Co added most to Moderna in Q4 2021, an estimated $1.04B increase.
- Baillie Gifford & Co's biggest Q4 2021 reduction was Tesla, cutting an estimated $3.07B.
- Baillie Gifford & Co fully exited Autohome in Q4 2021, selling an estimated $140M.
- Baillie Gifford & Co's ten largest holdings make up 40% of its $182B portfolio in Q4 2021.
- Baillie Gifford & Co opened 26 new positions and closed 19 in Q4 2021.
- Baillie Gifford & Co's portfolio value fell 4.7% quarter-over-quarter to $182B.
Based on Baillie Gifford & Co's 13F filing for Q4 2021, filed 20 Jan 2022.